Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment

Summary

Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment is a doctoral thesis^[1].

Key Facts

• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment authored Prakash Khadka^[2].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's instance of is recorded as doctoral thesis^[3].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's publisher is recorded as OUR Archive^[4].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's language of work or name is recorded as English^[5].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's country of origin is recorded as New Zealand^[6].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's publication date is recorded as +2021-00-00T00:00:00Z^[7].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's main subject is recorded as tuberculosis^[8].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's work available at URL is recorded as https://ourarchive.otago.ac.nz/handle/10523/10933^[9].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's Handle ID is recorded as 10523/10933^[10].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's title is recorded as Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment^[11].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's copyright holder is recorded as Prakash Khadka^[12].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's thesis submitted to is recorded as University of Otago^[13].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's on focus list of Wikimedia project is recorded as NZThesisProject^[14].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's copyright status is recorded as copyrighted^[15].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's thesis committee member is recorded as Shyamal C Das^[16].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's thesis committee member is recorded as Jack Dummer^[17].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's thesis committee member is recorded as Philip Hill^[18].
• Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's thesis committee member is recorded as Rajesh Katare^[19].

Body

Designation and Status

Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment's instance of is recorded as doctoral thesis^[3].